BIIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Biogen Inc (BIIB) is not a strong buy for a beginner, long-term investor at this time. While the company shows potential with upcoming catalysts and analyst optimism, its declining financial performance, insider selling, and lack of immediate growth drivers make it a less compelling choice for long-term investment. Holding off for clearer growth signals or a more favorable entry point is recommended.
The technical indicators are moderately positive. The MACD is above 0 and expanding, indicating bullish momentum. The RSI is neutral at 66.686, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 198.802 and 205.045, while support levels are at 178.59 and 172.347.
Analysts have raised price targets, with several maintaining Buy or Outperform ratings.
Biogen's Q4 2025 earnings exceeded expectations, showing strong execution.
Upcoming clinical trial readouts and R&D investments could drive future growth.
The appointment of Dr. Maria C. Freire as Chair of the Board brings expertise in biomedical innovation.
Financial performance in Q4 2025 showed a significant decline in revenue (-7.14% YoY), net income (-118.34% YoY), and EPS (-118.03% YoY).
Insiders are selling heavily, with a 864.10% increase in selling activity over the last month.
Hedge funds are neutral, indicating no strong institutional support.
Revenue growth drivers remain unclear, with analysts highlighting concerns about forward revenue trajectory.
In Q4 2025, Biogen reported revenues of $2.28 billion, down 7.14% YoY. Net income dropped to -$48.9 million (-118.34% YoY), and EPS fell to -$0.33 (-118.03% YoY). Gross margin slightly declined to 72.46%. Despite exceeding market expectations for Q4, the financials indicate a challenging growth environment.
Analysts are cautiously optimistic, with multiple firms raising price targets (e.g., Mizuho to $236, RBC to $233, Guggenheim to $246). However, concerns about revenue growth persist, and some analysts maintain Hold or Neutral ratings. The consensus reflects optimism about future catalysts but acknowledges current challenges.
